Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 2/2016

01-06-2016 | Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

New Developments in Assessing Risk of Local Recurrence in Patients with Ductal Carcinoma In Situ after Lumpectomy and Breast Radiation

Authors: Nafisha Lalani, Sharon Nofech-Mozes, Eileen Rakovitch

Published in: Current Breast Cancer Reports | Issue 2/2016

Login to get access

Abstract

Ductal carcinoma in situ of the breast comprises nearly 25 % of all diagnoses of breast cancer. The current paradigm for management of DCIS consists of breast-conserving surgery followed by post-operative radiotherapy. The goal of the treatment of DCIS is to reduce the risk of local recurrence (and invasive local recurrence) to prevent the detrimental psychological impact of recurrence and minimize the need for additional treatment. A number of clinical, pathological, and molecular variables have been identified as predictive markers of recurrence and can be used to help risk stratify women with this diagnosis. We present here a review of current markers of recurrence, risk prediction tools, and future directions.
Literature
1.
Ernster VL et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546–54.CrossRefPubMed
2.
Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6:CD001877.PubMed
3.
Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127(11):1023–8.CrossRefPubMed
4.•
Donker M et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31(32):4054–9 (Large randomized study of radiotherapy benefit).CrossRefPubMed
5.
Wapnir IL et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88.CrossRefPubMedPubMedCentral
6.
Ernster VL et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000;160:953–8.CrossRefPubMed
7.
(EBCTCG), E.B.C.T.C.G., et al., Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010, 2010: p. 162–177.
8.
Holmberg L et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247–52.CrossRefPubMed
9.
Cuzick J et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12(1):21–9.CrossRefPubMed
10.•
Allred DC et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–73 (Large randomised study of Tamoxifen benefit).CrossRefPubMedPubMedCentral
11.
Stuart KE et al. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015;15:890.CrossRefPubMedPubMedCentral
12.
Yen TW et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004;100(5):942–9.CrossRefPubMed
13.
Welch HG, Passow HJ. Quantifying the benefits and harms of screening mammography. JAMA Intern Med. 2014;174(3):448–54.CrossRefPubMed
14.
Welch HG, Frankel BA. Likelihood that a woman with screen-detected breast cancer has had her “life saved” by that screening. Arch Intern Med. 2011;171(22):2043–6.CrossRefPubMed
15.
Rakovitch E et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2007;101(2):335–47.CrossRefPubMed
16.
Baxter NN et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6):443–8.CrossRefPubMed
17.•
Rakovitch E et al. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat. 2013;138(2):581–90 (Risk assessment in DCIS).CrossRefPubMed
18.
Cutuli B et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience. Int J Radiat Oncol Biol Phys. 2002;2002:868–79.CrossRef
19.
Jhingran A et al. Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: the University of Texas M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 2002;2002:804–9.CrossRef
20.
Alvarado R et al. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012;19(12):3777–84.CrossRefPubMed
21.
Solin LJ et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103(6):1137–46.CrossRefPubMed
22.
Lalani, N., et al., Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. LID - S0360-3016(14)03533-0 [pii] LID - 10.1016/j.ijrobp.2014.07.026 [doi]. Int J Radiat Oncol Biol Phys. 2014. Sep. 11. pii. : S0360. -3016. (14)03533. -0. doi. : 10. 1016. /j. ijrobp. 2014. 07. 026, 2014: p. S0360-S3016.
23.
Vicini FA, Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol. 2002;20(11):2736–44.CrossRefPubMed
24.
Vicini FA et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol. 2000;18(2):296–6.PubMed
25.
Li CI et al. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer. 2006;106(10):2104–12.CrossRefPubMed
26.
Ben-David MA et al. Long-term results of conservative surgery and radiotherapy for ductal carcinoma in situ using lung density correction: the University of Michigan experience. Breast J. 2007;13(4):392–400.CrossRefPubMed
27.
Wang SY et al. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat. 2011;127(1):1–14.CrossRefPubMed
28.
Hiramatsu H et al. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: possible importance of family history. Cancer J Sci Am. 1995;1(1):55–61.PubMed
29.
Szelei-Stevens KA et al. The influence of young age and positive family history of breast cancer on the prognosis of ductal carcinoma in situ treated by excision with or without radiation therapy or by mastectomy. Int J Radiat Oncol Biol Phys. 2000;48(4):943–9.CrossRefPubMed
30.
31.
Shamliyan T et al. Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):121–9.CrossRefPubMed
32.
Collins LC et al. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013;139(2):453–60.CrossRefPubMedPubMedCentral
33.
Stark A et al. Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women. Breast Cancer Res Treat. 2012;131(2):561–70.CrossRefPubMedPubMedCentral
34.
Pinder SE et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer. 2010;103(1):94–100.CrossRefPubMedPubMedCentral
35.•
Rakovitch E et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152(2):389–98 (Validation of Oncotype DCIS assay).CrossRefPubMedPubMedCentral
36.•
Solin LJ et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10 (Oncotype DCIS assay).CrossRefPubMedPubMedCentral
37.
Di Saverio S et al. 259 patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008;109(3):405–16.CrossRefPubMed
38.
Macdonald HR et al. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. Am J Surg. 2006;192(4):420–2.CrossRefPubMed
39.•
Morrow M, Harris JR, Schnitt SJ. Surgical margins in lumpectomy for breast cancer—bigger is not better. N Engl J Med. 2012;367(1):79–82 (Discussion of margin threshold).CrossRefPubMed
40.
Warren JL et al. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS. Cancer. 2005;104(9):1840–8.CrossRefPubMed
41.
Dunne C et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27(10):1615–20.CrossRefPubMed
42.•
Wang SY et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst. 2012;104(7):507–16 (Meta-analysis of margin threshold).CrossRefPubMedPubMedCentral
43.
Kerlikowske K et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. JNCI Cancer Spectrum. 2003;95(22):1692–702.PubMed
44.
Collins LC et al. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009;33(12):1802–8.CrossRefPubMedPubMedCentral
45.
Lester, S.C., et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. 2009 [cited 2009; Available from: http://​www.​cap.​org/​apps/​docs/​committees/​cancer/​cancer_​protocols/​2009/​InvasiveBreast_​09protocol.​pdf.​]
46.•
Solin LJ et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;33(33):3938–44 (Prospective cohort study of local excission alone).CrossRefPubMed
47.
Badve S., G.R.J., Baehner F.L., Solin L.J., et al., Correlation between the DCIS Score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. J Clin Oncol, 2012. 30(Suppl; abstr1005).
48.•
Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999;86(3):429–38 (Randomized trial of radiation).CrossRefPubMed
49.
Miller NA et al. In situ duct carcinoma of the breast: clinical and histopathologic factors and association with recurrent carcinoma. Breast J. 2001;7(5):292–302.CrossRefPubMed
50.
Fisher ER et al. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am J Clin Pathol. 2007;128(1):86–91.CrossRefPubMed
51.
Smith BD et al. Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst. 2006;98(18):1302–10.CrossRefPubMed
52.
53.
Rakovitch E et al. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. J Clin Oncol. 2007;25(35):5591–6.CrossRefPubMed
54.
Wong JS et al. Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat. 2014;143(2):343–50.CrossRefPubMed
55.
56.
Roka S et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol. 2004;30(3):243–7.CrossRefPubMed
57.
Provenzano E et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer. 2003;39(5):622–30.CrossRefPubMed
58.
Curigliano G et al. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol. 2015;26(4):682–7.CrossRefPubMed
59.•
Rakovitch E et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012;106(6):1160–5 (Significance of Her2 + Ki67 in DCIS).CrossRefPubMedPubMedCentral
60.
Han, K., et al., Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol), 2011.
61.•
Borgquist S et al. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. 2015;15:468 (Her2 expression in DCIS).CrossRefPubMedPubMedCentral
62.
Noh JM et al. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy. Breast. 2013;22(5):894–7.CrossRefPubMed
63.
Williams KE et al. Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol. 2015;26(5):1019–25.CrossRefPubMed
64.
Kepple J et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J Surg. 2006;192(1):68–71.CrossRefPubMed
65.•
Ringberg A et al. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer. 2001;37(12):1514–22 (Significance of biomarkers in DCIS).CrossRefPubMed
66.
Chasle J et al. Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas—a preliminary study. Eur J Cancer. 2003;39(10):1363–9.CrossRefPubMed
67.•
Kerlikowske K et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. JNCI Journal of the National Cancer Institute. 2010;102(9):627–37 (Biomarkers in DCIS).CrossRefPubMedPubMedCentral
68.•
Kulkarni S et al. COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer. 2008;8:36 (Biomarkers in DCIS).CrossRefPubMedPubMedCentral
69.
Bundred NJ et al. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res. 2010;16(5):1605–12.CrossRefPubMed
70.•
Generali D et al. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Br J Cancer. 2014;111(1):46–54 (COX-2 expression in DCIS).CrossRefPubMedPubMedCentral
71.
Gauthier ML et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell. 2007;12(5):479–91.CrossRefPubMedPubMedCentral
72.
Barnes NL et al. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res. 2005;11(6):2163–8.CrossRefPubMed
73.
Rakovitch E et al. A large prospectively designed study of the DCIS score: recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation. San Antonio: Presented at the American Society for Radiation Oncology Annual Meeting; 2015.
Metadata
Title
New Developments in Assessing Risk of Local Recurrence in Patients with Ductal Carcinoma In Situ after Lumpectomy and Breast Radiation
Authors
Nafisha Lalani
Sharon Nofech-Mozes
Eileen Rakovitch
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 2/2016
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-016-0211-x

Other articles of this Issue 2/2016

Current Breast Cancer Reports 2/2016 Go to the issue

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Oncoplastic Breast Surgery: What, When and for Whom?

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Role of Breast MRI in Patients with Newly Diagnosed Breast Cancer

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Regional Nodal Radiotherapy in Early-Stage Breast Cancer: Where Are We in 2016?

Biomarkers (S Dawood, Section Editor)

Comprehensive Gene Mutation Profiling of Breast Tumors: Is It Ready for Prime Time Use?

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Nipple-Sparing Mastectomy in Patients with Germline BRCA Mutations: Is it Safe?

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Margins in Breast-Conserving Surgery for Early Breast Cancer: How Much is Good Enough?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits